The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).
 
Lauren Christine Harshman
Consulting or Advisory Role - Bayer; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech; Jounce Therapeutics; Merck; Michael J. Hennessy Associates; Novartis; Ology Medical Education; Pfizer; Theragene
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Endocyte (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst); Sotio (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Genentech
 
Michael Chu
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Teva
 
Saby George
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Pfizer; Sanofi
Research Funding - Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche
Research Funding - Amgen (Inst)
 
Bradley Curtis Carthon
Consulting or Advisory Role - Eisai
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Lawrence Fong
Consulting or Advisory Role - Atreca; BioAtla; Bolt Biotherapeutics; Nutcracker Therapeutics, Inc.; TeneoBio
Research Funding - Abbvie (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Jaime R. Merchan
Consulting or Advisory Role - Exelixis
Research Funding - Corvus Pharmaceuticals (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Replimune (Inst); Rexahn Pharmaceuticals (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Vyriad (Inst)
 
Long Kwei
Employment - Corvus Pharmaceuticals
Leadership - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals
 
Andrew N. Hotson
Employment - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Corvus Pharmaceuticals
 
Mehrdad Mobasher
Employment - Corvus Pharmaceuticals; Genentech
Leadership - Corvus Pharmaceuticals
Stock and Other Ownership Interests - Corvus Pharmaceuticals; Roche
Research Funding - Corvus Pharmaceuticals; Genentech
Travel, Accommodations, Expenses - Corvus Pharmaceuticals; Genentech
 
Richard A. Miller
Employment - Corvus Pharmaceuticals; Roche/Genentech (I)
Leadership - Corvus Pharmaceuticals; Genentech/Roche (I)
Stock and Other Ownership Interests - Bolt Biotherapeutics; Corvus Pharmaceuticals; Genentech/Roche (I)
Patents, Royalties, Other Intellectual Property - Inventor on patent application dealing with Corvus product under development